Trials / Completed
CompletedNCT02748512
Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
A Controlled, Multi-Center Study of the Utilization and Safety of the MkII Inserter and the Safety of the FAI Insert in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- EyePoint Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.
Detailed description
This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the MK II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FAI Insert administered using the Mk II inserter | |
| DRUG | FAI Insert administered using the Mk I inserter |
Timeline
- Start date
- 2016-02-23
- Primary completion
- 2017-08-17
- Completion
- 2017-08-17
- First posted
- 2016-04-22
- Last updated
- 2020-05-01
- Results posted
- 2020-05-01
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02748512. Inclusion in this directory is not an endorsement.